GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RepliCel Life Sciences Inc (OTCPK:REPCF) » Definitions » ROE % Adjusted to Book Value

RepliCel Life Sciences (RepliCel Life Sciences) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2023)


View and export this data going back to 2004. Start your Free Trial

What is RepliCel Life Sciences ROE % Adjusted to Book Value?

RepliCel Life Sciences's ROE % for the quarter that ended in Sep. 2023 was 0.00%. RepliCel Life Sciences's PB Ratio for the quarter that ended in Sep. 2023 was N/A. RepliCel Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was N/A.

RepliCel Life Sciences ROE % Adjusted to Book Value Historical Data

The historical data trend for RepliCel Life Sciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RepliCel Life Sciences ROE % Adjusted to Book Value Chart

RepliCel Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

RepliCel Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - Negative Equity - - -

Competitive Comparison of RepliCel Life Sciences's ROE % Adjusted to Book Value

For the Biotechnology subindustry, RepliCel Life Sciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RepliCel Life Sciences's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RepliCel Life Sciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where RepliCel Life Sciences's ROE % Adjusted to Book Value falls into.


RepliCel Life Sciences ROE % Adjusted to Book Value Calculation

RepliCel Life Sciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

RepliCel Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RepliCel Life Sciences ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of RepliCel Life Sciences's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

RepliCel Life Sciences (RepliCel Life Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RepliCel Life Sciences Inc (OTCPK:REPCF) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
TSX:APLI XCNQ:TRYP XCNQ:MESC TSXV:VXL XCNQ:MBIO XCNQ:CHGX TSXV:MRVL XCNQ:NOVA TSXV:IOT NEOE:AWKN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
P6P2:Germany P6P2:Germany RP:Canada
Address
570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1
Website
https://www.replicel.com
RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.